Novo Nordisk Challenges Existing Obesity Drugs With Promising New Early Stage Trial Results
The landscape of metabolic medicine is shifting once again as Novo Nordisk unveils data from a critical early stage clinical trial. The
by 
Josh Weiner
Josh Weiner